{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:02:41Z","timestamp":1779174161354,"version":"3.51.4"},"reference-count":24,"publisher":"Scientific Scholar","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"abstract":"\n Background & objectives:<\/jats:title>\n Uniform therapy for all leprosy patients will simplify leprosy treatment. In this context, we evaluated six-month multidrug therapy (MDT) currently recommended for multibacillary (MB) patients as uniform MDT (U-MDT) in a single-arm open trial under programme conditions. Primary objective was to determine efficacy to prevent five-year cumulative five per cent relapse. Secondary objectives were to assess acceptability, safety and compliance.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Newly detected, treatment-naive leprosy patients were enrolled in India (six sites) and P. R. China (two sites). Primary outcome was clinically confirmed relapse of occurrence of one or more new skin patches consistent with leprosy, without evidence of reactions post-treatment. Event rates per 100 person years as well as five-year cumulative risk of relapse, were calculated.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n A total of 2091 paucibacillary (PB) and 1298 MB leprosy patients were recruited from the 3437 patients screened. Among PB, two relapsed (rate=0.023; risk=0.11%), eight had suspected adverse drug reactions (ADRs) (rate=0.79) and rate of new lesions due toreactions was 0.24 (n=23). Rates of neuritis, type 1 and type 2 reactions were 0.39 (n=37), 0.54 (n=51) and 0.03 (n=3), respectively. Among MB, four relapsed (rate=0.07; risk=0.37%) and 16 had suspected ADR (rate=2.64). Rate of new lesions due to reactions among MB was 1.34 (n=76) and rates of neuritis, type 1 and type 2 reactions were 1.37 (n=78), 2.01 (n=114) and 0.49 (n=28), respectively. Compliance to U-MDT was 99 per cent. Skin pigmentation due to clofazimine was of short duration and acceptable.<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions:<\/jats:title>\n We observed low relapse, minimal ADR and other adverse clinical events. Clofazimine-related pigmentation was acceptable. Evidence supports introduction of U-MDT in national leprosy programmes. [CTRI No: 2012\/ 05\/ 002696]<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0971-5916.200888","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:07:40Z","timestamp":1734635260000},"page":"525-535","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["International open trial of uniform multidrug therapy regimen for leprosy patients"],"prefix":"10.25259","volume":"144","author":[{"given":"Ponnaiah","family":"Manickam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay M.","family":"Mehendale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bathyala","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Katoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Jamesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramalingam","family":"Kutaiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen","family":"Jianping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivakumar","family":"Mugudalabetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitthal","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabu","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayasree","family":"Padma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanagasabai","family":"Kaliaperumal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayakumar","family":"Pannikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padabettu","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan D.","family":"Gupte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"R6-7-20241212","doi-asserted-by":"crossref","first-page":"2","DOI":"10.47276\/lr.74.1.2","article-title":"Uniform MDT (U-MDT) regimen for all leprosy patients \u2013 Another example of wishful thinking","volume":"74","author":"Ji","year":"2003","journal-title":"Lepr Rev"},{"key":"R7-7-20241212","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-3156.2008.02045.x","article-title":"International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results","volume":"13","author":"Kroger","year":"2008","journal-title":"Trop Med Int Health"},{"key":"R8-7-20241212","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.40.2.393","article-title":"Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice","volume":"40","author":"Ji","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-7-20241212","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/AAC.41.2.326","article-title":"Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy","volume":"41","author":"Banerjee","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-7-20241212","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.40.9.2137","article-title":"Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients","volume":"40","author":"Ji","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-7-20241212","first-page":"311","article-title":"Chemotherapy trial in paucibacillary leprosy using clofazimine","volume":"71","author":"Katoch","year":"1999","journal-title":"Indian J Lepr"},{"key":"R14-7-20241212","doi-asserted-by":"crossref","first-page":"308","DOI":"10.47276\/lr.83.3.308","article-title":"Primary results of clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT\/CT-BR): reactions frequency in multibacillary patients","volume":"83","author":"Penna","year":"2012","journal-title":"Lepr Rev"},{"key":"R15-7-20241212","doi-asserted-by":"crossref","first-page":"262","DOI":"10.47276\/lr.85.4.262","article-title":"Results from the clinical trial of uniform multidrug therapy for leprosy patients in Brazil (U-MDT\/CT-BR):decrease in bacteriological index","volume":"85","author":"Penna","year":"2014","journal-title":"Lepr Rev"},{"key":"R19-7-20241212","doi-asserted-by":"crossref","first-page":"65","DOI":"10.47276\/lr.82.1.65","article-title":"Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines","volume":"82","author":"Maghanoy","year":"2011","journal-title":"Lepr Rev"},{"key":"R20-7-20241212","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clindermatol.2014.07.007","article-title":"Treatment of leprosy","volume":"33","author":"Kar","year":"2015","journal-title":"Clin Dermatol"},{"key":"R23-7-20241212","first-page":"189","article-title":"Leprosy beyond MDT: study of follow-up of 100 released from treatment cases","volume":"82","author":"Vara","year":"2010","journal-title":"Indian J Lepr"},{"key":"R24-7-20241212","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ije\/dyg225","article-title":"Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up","volume":"33","author":"Richardus","year":"2004","journal-title":"Int J Epidemiol"},{"key":"R25-7-20241212","doi-asserted-by":"crossref","first-page":"14","DOI":"10.47276\/lr.76.1.14","article-title":"The INFIR cohort study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India","volume":"76","author":"van Brakel","year":"2005","journal-title":"Lepr Rev"},{"key":"R26-7-20241212","doi-asserted-by":"crossref","first-page":"164","DOI":"10.47276\/lr.80.2.164","article-title":"Occurrence and management of leprosy reaction in China in 2005","volume":"80","author":"Shen","year":"2009","journal-title":"Lepr Rev"},{"key":"R27-7-20241212","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4269\/ajtmh.13-0221","article-title":"Risk factors for leprosy reactions in three endemic countries","volume":"92","author":"Scollard","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"R28-7-20241212","first-page":"309","article-title":"Reversal reactions in the skin lesions of AMFES patients: incidence and risk factors","volume":"71","author":"Saunderson","year":"2000","journal-title":"Lepr Rev"},{"key":"R29-7-20241212","first-page":"S106","article-title":"The epidemiology of reactions and nerve damage","volume":"71","author":"Saunderson","year":"2000","journal-title":"Lepr Rev"},{"key":"R30-7-20241212","first-page":"173","article-title":"Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia","volume":"60","author":"Becx-Bleumink","year":"1992","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"R31-7-20241212","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1590\/0074-0276130222","article-title":"Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy","volume":"108","author":"Antunes","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"R32-7-20241212","doi-asserted-by":"crossref","first-page":"868","DOI":"10.4269\/ajtmh.2006.74.868","article-title":"Clinical course of erythema nodosumleprosum: an 11-year cohort study in Hyderabad, India","volume":"74","author":"Pocaterra","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"R33-7-20241212","doi-asserted-by":"crossref","first-page":"e2440","DOI":"10.1371\/journal.pntd.0002440","article-title":"A systematic review on the epidemiological data of erythema nodosumleprosum, a type 2 leprosy reaction","volume":"7","author":"Voorend","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"R34-7-20241212","doi-asserted-by":"crossref","first-page":"637","DOI":"10.4269\/ajtmh.2010.09-0586","article-title":"Reactions following completion of 1 and 2 year multidrug therapy (MDT)","volume":"83","author":"Balagon","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"R37-7-20241212","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/ijd.12573","article-title":"Six years\u2019 follow-up of multibacillary leprosy patients treated with uniform multi-drug therapy in China","volume":"54","author":"Shen","year":"2015","journal-title":"Int J Dermatol"},{"key":"R38-7-20241212","doi-asserted-by":"crossref","first-page":"164","DOI":"10.47276\/lr.83.2.164","article-title":"Bacteriological results and leprosy reactions among MB leprosy patients treated with uniform multidrug therapy in China","volume":"83","author":"Shen","year":"2012","journal-title":"Lepr Rev"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201644040-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:58:22Z","timestamp":1751497102000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/international-open-trial-of-uniform-multidrug-therapy-regimen-for-leprosy-patients-findings-implications-for-national-leprosy-programmes\/"}},"subtitle":["Findings & implications for national leprosy programmes"],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0971-5916.200888","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}